OTCPK:TDMM.F

Stock Analysis Report

Executive Summary

Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability solutions for healthcare enterprises worldwide.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Risks

  • Mach7 Technologies has significant price volatility in the past 3 months.
  • Mach7 Technologies is covered by less than 3 analysts.

Share Price & News

How has Mach7 Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.1%

TDMM.F

2.5%

US Healthcare Services

-0.6%

US Market


1 Year Return

n/a

TDMM.F

10.3%

US Healthcare Services

0.6%

US Market

No trading data on TDMM.F.

No trading data on TDMM.F.


Share holder returns

TDMM.FIndustryMarket
7 Day-1.1%2.5%-0.6%
30 Day-21.3%-2.9%2.2%
90 Dayn/a-4.1%1.1%
1 Yearn/a10.4%10.3%2.9%0.6%
3 Yearn/a51.9%51.6%44.6%35.2%
5 Yearn/a52.0%51.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is Mach7 Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mach7 Technologies undervalued based on future cash flows and its price relative to the stock market?

8.89x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Mach7 Technologies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Mach7 Technologies to establish if it is available at substantial discount.


Price Based on Earnings

Mach7 Technologies is loss making, we can't compare its value to the US Healthcare Services industry average.

Mach7 Technologies is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Mach7 Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

Mach7 Technologies is overvalued based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is Mach7 Technologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

24.4%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Mach7 Technologies's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if Mach7 Technologies is high growth as no earnings estimate data is available.

Mach7 Technologies's revenue growth is expected to exceed the United States of America market average.

Unable to compare Mach7 Technologies's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare Mach7 Technologies's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Mach7 Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Mach7 Technologies performed over the past 5 years?

-0.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Mach7 Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Mach7 Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Mach7 Technologies's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Mach7 Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Mach7 Technologies has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Mach7 Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Mach7 Technologies's financial position?


Financial Position Analysis

Mach7 Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Mach7 Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Mach7 Technologies's level of debt (5.8%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Mach7 Technologies's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 9.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Mach7 Technologies has less than a year of cash runway based on current free cash flow.

Mach7 Technologies has less than a year of cash runway if free cash flow continues to reduce at historical rates of -10.1% each year.


Next Steps

Dividend

What is Mach7 Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Mach7 Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Mach7 Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Mach7 Technologies has not reported any payouts.

Unable to verify if Mach7 Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Mach7 Technologies has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Mach7 Technologies's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Mach7 Technologies's salary, the management and board of directors tenure and is there insider trading?

0.4yrs

Average management tenure


CEO

Mach7 Technologies has no CEO, or we have no data on them.


Management Age and Tenure

0.4yrs

Average Tenure

The average tenure for the Mach7 Technologies management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

The average tenure for the Mach7 Technologies board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellAU$407,31204 Jul 19
Australian Ethical Investment Ltd
EntityCompany
Shares1,115,957
Max PriceAU$0.38
BuyAU$1,127,21810 Apr 19
JM Financial Group
EntityCompany
Shares8,175,951
Max PriceAU$0.14
SellAU$44,53110 Apr 19
JM Financial Group
EntityCompany
Shares334,180
Max PriceAU$0.13
BuyAU$421,54609 Apr 19
Australian Ethical Investment Ltd
EntityCompany
Shares3,027,379
Max PriceAU$0.14
SellAU$1,296,07408 Apr 19
Oceania Capital Partners Limited
EntityCompany
Shares9,243,933
Max PriceAU$0.14
SellAU$248,50501 Apr 19
Oceania Capital Partners Limited
EntityCompany
Shares1,998,522
Max PriceAU$0.13
SellAU$359,76720 Mar 19
JM Financial Group
EntityCompany
Shares1,969,072
Max PriceAU$0.18
BuyAU$1,137,10520 Mar 19
JM Financial Group
EntityCompany
Shares7,216,280
Max PriceAU$0.16
SellAU$169,63628 Feb 19
Oceania Capital Partners Limited
EntityCompany
Shares1,180,698
Max PriceAU$0.15
BuyAU$6,43103 Oct 18
David Chambers
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares42,399
Max PriceAU$0.15

Ownership Breakdown


Management Team

  • Jenni Pilcher

    Global CFO & Corporate Secretary

    • Tenure: 0yrs
    • Compensation: AU$388.20k
  • Mike Lampron

    MD & Director

    • Tenure: 0.3yrs
    • Compensation: AU$307.76k
  • Ravi Krishnan

    Founder & Chief Strategy Officer

    • Tenure: 2.5yrs
    • Compensation: AU$363.18k
  • John Rice

    Consultant

    • Tenure: 0.5yrs
    • Compensation: AU$354.33k
  • Travis Nuzzi

    Vice President of Sales and Marketing

    • Tenure: 0.3yrs

Board Members

  • Per Larsen (63yo)

    Member of Industry Advisory Board

    • Tenure: 1.5yrs
  • Damien Lim (56yo)

    Non-Executive Director

    • Tenure: 3.4yrs
    • Compensation: AU$61.10k
  • Eliot Siegel

    Non-Executive Director

    • Tenure: 1.1yrs
  • David Chambers

    Chairman of the Board

    • Tenure: 0.3yrs
  • Mike Lampron

    MD & Director

    • Tenure: 0.3yrs
    • Compensation: AU$307.76k
  • Alister Spittle

    Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: AU$36.03k
  • James Alland

    Member of Industry Advisory Board

    • Tenure: 0yrs
  • Francisco Sapori

    Member of Industry Advisory Board

    • Tenure: 0yrs
  • Sean Moynihan

    Member of Industry Advisory Board

    • Tenure: 0yrs
  • Jeff Weil

    Member of Industry Advisory Board

    • Tenure: 0yrs

Company Information

Mach7 Technologies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mach7 Technologies Limited
  • Ticker: TDMM.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$93.189m
  • Listing Market Cap: AU$63.093m
  • Shares outstanding: 150.30m
  • Website: https://www.mach7t.com

Number of Employees


Location

  • Mach7 Technologies Limited
  • 120 Kimball Avenue
  • Suite 210
  • South Burlington
  • Vermont
  • 5403
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
M7TASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 2016
TDMM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2016

Biography

Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability solutions for healthcare enterprises worldwide. It offers Management Studio that enables healthcare delive ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:50
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.